Hematology Oncology 2015
241 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by oncdoc7
Scoop.it!

Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment - Bassan - 2016 - European Journal of Haematology - Wiley Online Library

Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment - Bassan - 2016 - European Journal of Haematology - Wiley Online Library | Hematology Oncology 2015 | Scoop.it
more...
No comment yet.
Rescooped by oncdoc7 from Cancer Immunotherapy Review
Scoop.it!

ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer Types

ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer Types | Hematology Oncology 2015 | Scoop.it
The class of cancer immunotherapy drugs which target the protein PD-1 is proving to be effective against advanced liver, head and neck, lung and colon cancers.

 

Merck's Keytruda demonstrated a 62% tumor shrinkage in patients with advanced colon cancer containing a newly discovered genetic biomarker.The tumor response rate to Bristol's Opdivo in patients with advanced liver cancer was 19%. The overall survival rate at 12 months was 62%. While early, the results suggest Opdivo may have a role to play in the treatment of the disease where only a single targeted drug has proven effective.In a study of patients with head and neck cancer, Merck's Keytruda demonstrated a tumor response rate of 25%, or more than double the response typically seen with Eli Lilly's Erbitux.In the only randomized study discussed Friday enrolling patients with advanced, non-squamous, non-small cell lung cancer (the most common form of lung cancer) treatment with Bristol's Opdivo led to a 27% reduction in the risk of death compared to a placebo. Patients with tumors expressing high levels of the protein PD-1 lived even longer.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 29, 2015 3:20 PM

Adam Feuerstein

 

Bristol's Opdivo shrunk liver cancer in eight of 42 patients evaluable in a phase I study. The 19% objective response rate was especially encouraging because three-quarters of the patients enrolled in the study had liver cancer progressing despite previous treatments. Nearly 70% of the patients were treated previously withAmgen's (AMGN) Nexavar -- the only targeted drug approved currently for liver cancer.

Rescooped by oncdoc7 from Cancer Immunotherapy Review
Scoop.it!

KEYTRUDA® (pembrolizumab, Merck) Anti-PD-1 Therapy Effective in Advanced Head and Neck Cancer. ASCO 2015

KEYTRUDA® (pembrolizumab, Merck) Anti-PD-1 Therapy Effective in  Advanced Head and Neck Cancer. ASCO 2015 | Hematology Oncology 2015 | Scoop.it

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA®(pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with recurrent or metastatic head and neck cancer, regardless of PD-L1 expression status. In the evaluable patients, the overall response rate (ORR) (confirmed and unconfirmed) was 24.8 percent for KEYTRUDA (200 mg fixed dose every three weeks) (n=29/117) (95% CI, 17.3-33.6). When looking at HPV status, the ORR was similar among HPV-positive and HPV-negative disease (20.6 percent [n=7/34] and 27.2 percent [n=22/81], respectively) (95% CI, 8.7-37.9 and 17.9-38.2). These data, featured in the ASCO Press Program today, will be presented in an oral session by Dr. Tanguy Seiwert, The University of Chicago, on Monday, June 1 at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #LBA6008).

Merck has initiated a comprehensive clinical development program for KEYTRUDA evaluating a fixed dosing regimen (200 mg every three weeks) in head and neck cancer across multiple lines of therapy as monotherapy and in combination with chemotherapy and other agents. Results from KEYNOTE-012 were first presented at the 2014 ASCO Annual Meeting and showed 19.6 percent ORR for KEYTRUDA (10 mg/kg every two weeks) in heavily pre-treated patients with advanced head and neck cancer with tumor cells positive for PD-L1 expression.

 

KEYNOTE-012 Study

KEYNOTE-012 is an ongoing multi-center, non-randomized Phase 1b trial evaluating the safety, tolerability and anti-tumor activity of KEYTRUDA monotherapy (10 mg/kg every two weeks or 200 mg IV every three weeks) in patients with advanced triple negative breast cancer (TNBC), advanced head and neck cancer, advanced urothelial cancer, or advanced gastric cancer. The primary endpoints of the study include overall safety, tolerability, and anti-tumor activity (as measured by RECIST v1.1); secondary endpoints include progression-free survival (PFS), overall survival (OS), and duration of response.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 30, 2015 11:15 AM
New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status

Results from KEYNOTE-012, the First and Largest Study to Date of an Anti-PD-1 Therapy in Head and Neck Cancer, to be Presented at 2015 ASCO Annual Meeting

KEYTRUDA Monotherapy Achieved Overall Response Rate of 25 Percent in Heavily Pre-treated Patients

Merck is Advancing a Broad Head and Neck Clinical Program for KEYTRUDA with Five Clinical Trials, Across Multiple Lines of Therapy and in Combination with Other Agents

Rescooped by oncdoc7 from PARP Inhibitors Cancer Review
Scoop.it!

ASCO 2015: Report from Day 1

ASCO 2015: Report from Day 1 | Hematology Oncology 2015 | Scoop.it
A day for travel and educational sessions at the American Society of Clinical Oncology (ASCO).

Via Krishan Maggon
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

WINS Trial: Weight Loss from Low-Fat Diet Improves Survival in HR-Negative Breast Cancer

WINS Trial: Weight Loss from Low-Fat Diet Improves Survival in HR-Negative Breast Cancer | Hematology Oncology 2015 | Scoop.it
oncdoc7's insight:

56% reduction in mortality with weight loss alone in HR negative 

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients with Relapsed MM: Interim Results from ASPIRE

Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients with Relapsed MM: Interim Results from ASPIRE | Hematology Oncology 2015 | Scoop.it
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma | Hematology Oncology 2015 | Scoop.it

20/23 

oncdoc7's insight:

20 out of 23 patients responded to Nivolumab

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

ASCO Video Conference Reporter ASH

ASCO Video Conference Reporter ASH | Hematology Oncology 2015 | Scoop.it
oncdoc7's insight:

FIRST TRIAL - Shaji Kumar -  Continous Rd better than MPT in myeloma even age>75.

more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Emerging payment systems fuel cancer care consolidation - part III - Oncology Times - Lola Butcher

An abstract is unavailable.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Unintended Consequences: How Government Policies Have Increa... : Oncology Times

An abstract is unavailable.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

FIRE-3 Study: Cetuximab Versus Bevacizumab in mCRC

FIRE-3 Study: Cetuximab Versus Bevacizumab in mCRC | Hematology Oncology 2015 | Scoop.it
oncdoc7's insight:

In KRAS WILD TYPE, Cetuximab improved OS, though rr and dfs were same as Avastin.  Video

more...
No comment yet.
Rescooped by oncdoc7 from Cancer Immunotherapy Review
Scoop.it!

KEYTRUDA® (pembrolizumab, Merck ) New Studies Melanoma, breast cancer TNBC & NHL.

KEYTRUDA® (pembrolizumab, Merck ) New Studies Melanoma, breast cancer TNBC & NHL. | Hematology Oncology 2015 | Scoop.it

 Merck MRK, known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the company’s anti-PD-1 therapy – in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov. 13 – 16, the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 – 9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 – 13, respectively. By the end of 2014, data on anti-tumor activity of KEYTRUDA as monotherapy will have been presented in seven different tumor types.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, November 7, 2014 1:41 AM

About KEYTRUDA (pembrolizumab)

KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

Rescooped by oncdoc7 from Cancer Immunotherapy Review
Scoop.it!

ASTRAZENECA AND MEDIMMUNE PRESENT POSITIVE IMMUNO-ONCOLOGY COMBINATION DATA AT ASCO 2015

ASTRAZENECA AND MEDIMMUNE PRESENT POSITIVE IMMUNO-ONCOLOGY COMBINATION DATA AT ASCO 2015 | Hematology Oncology 2015 | Scoop.it

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015. 

 

Overall, data indicated clinical activity with manageable safety profiles for the anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody MEDI4736, both as monotherapy and in combination with other immuno-oncology and small molecule therapies across different tumour types and tumour biology.

 

 

Results from the combination study of MEDI4736 and tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) monoclonal antibody, in the treatment of advanced NSCLC demonstrated clinical activity in heavily-pretreated patients with a manageable safety profile, establishing appropriate doses to move forward into Phase III combination trials.

 

MEDI4736 and tremelimumab target two different tumour escape pathways; engaging the immune system to fight the cancer’s immune-evading tactics and maintaining tumour specific T-cell responses.

 

Data from the Phase Ib open label, dose escalation study of patients with advanced NSCLC, showed that the combination of the PD-L1 and CTLA-4 blockade helped to increase response rates in both PD-L1 biomarker positive and negative patients. 63 patients with 16 weeks or more of follow up were evaluable for clinical activity, 102 patients were evaluated for safety. Notably, the data demonstrated specific clinical activity and tolerability in PDL-1 negative patients, who make up approximately 70% of NSCLC patients and who are less likely to respond to monotherapy. In the PD-L1 negative patient subset, overall response rate (ORR) was 27% (9/33) and disease control rate (DCR) – defined as complete response (CR), partial response (PR) or stable disease (SD) for 16 weeks or more -  was 48% (16/33). Overall, nearly half of patients in the study achieved a partial response or stable disease, with ORR of 27% (17/63) and DCR of 41% (26/63). (Antonia et al, abstract #3014).


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 30, 2015 10:25 AM

MEDI4736 and tremelimumab combination shows clinical activity and tolerability in both PD-L1 positive and PD-L1 negative advanced non-small cell lung cancer (NSCLC) patients; dose confirmed for future studies


Data reinforce the potential of MEDI4736 as a cornerstone for combinations with other immunotherapies and small molecule treatments in multiple tumour types


Positive progress with companion diagnostic test to help identify patients who are more likely to respond to MEDI4736, reinforcing personalised healthcare approach

Rescooped by oncdoc7 from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Seattle Genetics Antibody-Drug Conjugates data ASCO 2015

Seattle Genetics Antibody-Drug Conjugates  data  ASCO 2015 | Hematology Oncology 2015 | Scoop.it

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting

BOTHELL, Wash.--(BUSINESS WIRE)--May 28, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted in more than 10 sessions at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting being held May 29 to June 2, 2015 in Chicago, IL. Presentations will feature data from several corporate and investigator-sponsored trials with ADCETRIS® (brentuximab vedotin), including additional analyses from the phase 3 AETHERA clinical trial and updated data in frontline diffuse large B-cell lymphoma (DLBCL). In addition, the company’s ADC collaborators, including Genentech (a member of the Roche Group), AbbVie, Genmab and Agensys (an affiliate of Astellas), will report data from clinical programs using Seattle Genetics’ ADC technology. Seattle Genetics will also present preclinical data from its novel SEA-CD40 immuno-oncology candidate currently being evaluated in a phase 1 clinical trial.

Seattle Genetics is evaluating its ADC technology broadly through ADCETRIS, proprietary pipeline and collaborator programs. The company is leading the field in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition, Seattle Genetics is building on expertise in empowered, targeted approaches for the treatment of cancer in advancing its proprietary sugar-engineered antibody (SEA) technology, a novel technology designed to increase the potency of monoclonal antibodies through glycoengineering which may lead to an improved antitumor immune response.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 29, 2015 1:39 AM

Saturday, May 30, 2015

A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors (Seattle Genetics; Abstract #3074, poster presentation)A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC in patients with solid tumors (Genmab; Abstract #2570, poster presentation)Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers (Genmab; Abstract #3066, poster presentation)ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR) (AbbVie; Abstract #2510, poster presentation)STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC) (Genentech; Abstract #5029, poster presentation)

Monday, June 1, 2015

Updated results of a phase 2 trial of brentuximab vedotin combined with RCHOP in frontline treatment of pts with high-intermediate/high-risk DLBCL (Seattle Genetics; Abstract #8506, oral presentation 11:21 a.m. CT)Quality of life EQ-5D results from the AETHERA trial: a phase 3 study of brentuximab vedotin consolidation following autologous stem cell transplant for HL (Seattle Genetics; Abstract #6568, poster presentation)Brentuximab vedotin plus AVD for non-bulky limited stage classical Hodgkin lymphoma: a phase 2 trial (Investigator-sponsored; Abstract #8505, oral presentation 11:09 a.m. CT)Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level (Genentech; Abstract #8503, oral presentation 9:45 a.m. – 12:45 p.m. CT)Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM) (AbbVie; Abstract #2016, poster presentation)

Tuesday, June 2, 2015

Ph 1 studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RCC) (Agensys; Abstract #2503, oral presentation 8:00 – 11:00 a.m. CT)

Rescooped by oncdoc7 from PARP Inhibitors Cancer Review
Scoop.it!

Portola Pharma ASCO 2015 Cerdulatinib Dual SYK-JAK inhibitor Clinical Update

Portola Pharma ASCO 2015  Cerdulatinib Dual SYK-JAK inhibitor Clinical Update | Hematology Oncology 2015 | Scoop.it

Portola Pharmaceuticals 

 

SOUTH SAN FRANCISCO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals(Nasdaq:PTLA) today announced updated positive safety and efficacy data from the Phase 1 part of its ongoing Phase 1/2a proof-of-concept study of cerdulatinib in patients with hematologic cancers who have failed multiple therapies. Cerdulatinib is an oral, dual Syk-JAK kinase inhibitor that Portola is developing to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded to prior therapies. The new data will be presented on Sunday, May 31, in a poster discussion session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting inChicago. The Company previously presented interim data from the Phase 1 part of the study at theAmerican Society of Hematology (ASH) 2014 Annual Meeting in December 2014.

 

The results to be presented at ASCO demonstrated evidence of clinical activity in this study of patients with relapsed/refractory B-cell malignancies. To date, partial responses have been observed, including in patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and transformed FL. Tumor reductions were seen in multiple patients, including those whose disease progressed on (or who could not tolerate) other BCR pathway inhibitors. Results also showed that cerdulatinib was well tolerated in these heavily pre-treated patients, with no dose-limiting toxicities identified. Grade 3/4 adverse events included fatigue. Dose-escalation is ongoing in the Phase 1 part of the study as the maximum tolerated dose has not yet been achieved.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 30, 2015 9:59 AM
Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib--Oral, Dual Syk-JAK Kinase Inhibitor Continues to Demonstrate Clinical Proof of Concept in Hematologic Cancer Patients Who Have Failed Prior Therapies--
Scooped by oncdoc7
Scoop.it!

WINS Trial: Weight Loss from Low-Fat Diet Improves Survival in HR-Negative Breast Cancer

WINS Trial: Weight Loss from Low-Fat Diet Improves Survival in HR-Negative Breast Cancer | Hematology Oncology 2015 | Scoop.it
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory MM

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory MM | Hematology Oncology 2015 | Scoop.it
more...
No comment yet.
Rescooped by oncdoc7 from #ASCO13 #ASH13 #SABCS13 #GI14 #GU14
Scoop.it!

OBR Peer Reviews - Robert Figlin, MD and Nicholas Vogelzang, MD - ASCO GU 2014 - YouTube

Robert Figlin, MD and Nicholas Vogelzang, MD discuss effects of data released at the ASCO 2014 GU Symposium. FOCUS ON: PROSTATE CANCER. http://www.obroncolog...
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

340-B drug discounts have fueled migration of cancer care to hospitals

An abstract is unavailable.
more...
No comment yet.
Scooped by oncdoc7
Scoop.it!

ASH14 Meeting Preview: Picks from ASH President Linda Burns,... : Oncology Times

An abstract is unavailable.
more...
No comment yet.
Rescooped by oncdoc7 from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

Bleeding risk from new blood thinner Pradaxa higher than first reported

Bleeding risk from new blood thinner Pradaxa higher than first reported | Hematology Oncology 2015 | Scoop.it
The FDA’s approval in 2010 of the blood-thinner dabigatran (Pradaxa) got many doctors excited. This drug got the green light after a head-to-head trial with warfarin (generic, Coumadin) in people with an irregular heart beat from atrial fibrillation.

 

ABSTRACT 

Importance  It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice.

 

Objective  To compare the risk of bleeding associated with dabigatran and warfarin using Medicare data.

 

Design, Setting, and Participants  In this retrospective cohort study, we used pharmacy and medical claims in 2010 to 2011 from a 5% random sample of Medicare beneficiaries. We identified participants as those newly diagnosed as having atrial fibrillation from October 1, 2010, through October 31, 2011, and who initiated dabigatran or warfarin treatment within 60 days of initial diagnosis. We followed up patients until discontinued use or switch of anticoagulants, death, or December 31, 2011.

 

Exposures  Dabigatran users (n = 1302) and warfarin users (n = 8102).

 

Main Outcomes and Measures  We identified any bleeding events and categorized them as major and minor bleeding by anatomical site. Major bleeding events included intracranial hemorrhage, hemoperitoneum, and inpatient or emergency department stays for hematuria, gastrointestinal, or other hemorrhage. We used a propensity score weighting mechanism to balance patient characteristics between 2 groups and Cox proportional hazards regression models to evaluate the risk of bleeding. We further examined the risk of bleeding for 4 subgroups of high-risk patients: those 75 years or older, African Americans, those with chronic kidney disease, and those with more than 7 concomitant comorbidities.

 

Results  Dabigatran was associated with a higher risk of bleeding relative to warfarin, with hazard ratios of 1.30 (95% CI, 1.20-1.41) for any bleeding event, 1.58 (95% CI, 1.36-1.83) for major bleeding, and 1.85 (95% CI, 1.64-2.07) for gastrointestinal bleeding. The risk of intracranial hemorrhage was higher among warfarin users, with a hazard ratio of 0.32 (95% CI, 0.20-0.50) for dabigatran compared with warfarin. Dabigatran was consistently associated with an increased risk of major bleeding and gastrointestinal hemorrhage for all subgroups analyzed. The risk of major bleeding among dabigatran users was especially high for African Americans and patients with chronic kidney disease.

 

Conclusions and Relevance  Dabigatran was associated with a higher incidence of major bleeding (regardless of the anatomical site), a higher risk of gastrointestinal bleeding, but a lower risk of intracranial hemorrhage. Thus, dabigatran should be prescribed with caution, especially among high-risk patients.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, November 6, 2014 3:11 AM
Original Investigation | November 03, 2014Risk of Bleeding With Dabigatran in Atrial FibrillationONLINE FIRSTInmaculada Hernandez, PharmD1; Seo Hyon Baik, PhD1; Antonio Piñera, MD2; Yuting Zhang, PhD1[+] Author AffiliationsJAMA Intern Med. Published online November 03, 2014. doi:10.1001/jamainternmed.2014.5398Text Siz